



Ref: Syn/CS/SE/2024-25/Feb/04

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

February 10, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 –Leadership changes

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI Listing Regulations”) read with clause 7 and 7C of Para A of Part A of Schedule III of the SEBI Listing Regulations, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, the Board of Directors has approved leadership changes as stated in **Annexure 1**.

The resignation letter of Mr. Jonathan Hunt is attached as **Annexure 2**.

The above information will also be made available on the website of the Company at www.syngeneintl.com.

Kindly take the above information on record.

Thanking You

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Priyadarshini Mahapatra
Head Legal, Company Secretary & Compliance Officer
Encl: a/a

Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:

S. No.	Particulars		
1.	Name	Jonathan Hunt	Peter Bains
2.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)	Resignation from the position of the Managing Director and Chief Executive Officer; as well as the Board of Directors and Key Managerial Personnel (KMP) of the Company to pursue new opportunities.	Appointment as the Chief Executive Officer – Designate (Non- KMP).
3.	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/re-appointment;	Resignation with effect from February 10, 2025	Appointment with effect from February 10, 2025
4.	Brief profile	Not Applicable	Brief profile attached as Annexure 1A
5.	Disclosure of relationship (in case of appointment)	Not Applicable	None.

Brief Profile of Mr. Peter Bains:

Mr. Peter Bains, 67 years, holds a bachelor's degree in Science (Combined honours in Zoology and Physiology) from University of Sheffield, United Kingdom. He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels with an extensive track record of leadership and success in building companies, businesses, teams and brands for over 30 years. Peter brings in differentiating characteristics with extensive experience in Biopharmaceuticals across business and technology segmentation (Biotech, Vaccines, Branded Generics, Life Sciences, CRO) and geography encompassing both developed and emerging markets.

Peter, currently, the Group CEO of Biocon Group, served as CEO and Member of the Board of Syngene International Limited for almost 6 years from 2010, and led the Company to its successful public listing in 2015. He also served as CEO of Sosei Group, a Japanese listed biopharmaceutical company. Prior to this, Peter worked with GlaxoSmithKline over a period of 23 years, where he held several roles including Head of Global Marketing and Senior Vice President of commercial development for GSK's International region.

Jonathan Hunt

Chief Executive Officer and Managing Director
Syngene International Ltd

10th February 2025

Chairman of the Board of Directors

Syngene International Ltd
Biocon Park, Bangalore, India

Dear Kiran,

Following nine years in the role of CEO and Managing Director of Syngene International, and after much reflection, I have taken the decision to inform the Board of Directors of my intention to resign as CEO and Managing Director and to stand down from the Board of Directors with immediate effect to take up new opportunities both personally and professionally.

During my tenure, Syngene has grown to become a successful and globally recognised player within our sector and along the way, I have had the pleasure of working alongside a talented leadership team and dedicated employees to achieve many significant milestones, including expanding our operations into multiple new areas of science, creating thousands of scientific jobs, establishing Syngene as the leading CRDMO in Animal Health as well as India's emerging leader in biologics CDMO and in doing this, creating exceptional shareholder value.

I believe it is now the right time for me to move into the next phase of my professional life. This decision was not made lightly, and I remain fully committed to supporting a seamless transition and to fully support this, my services will be available as required to Syngene up to 6th June 2025.

I have every confidence in the company's strategic direction, and I am and will remain proud to have led Syngene and all we have accomplished together, and I look forward to seeing the continued success of the company.

On a personal note, it has been a pleasure working alongside you and I leave with many fond memories of the time we have spent together. Please feel free to reach out to discuss how I can best support the transition process.

Sincerely,

Jonathan Hunt
Chief Executive Officer
Syngene International